Takeda’s Millennium Seeks Modest Acquisitions, But Could Go Bigger
This article was originally published in PharmAsia News
Executive Summary
Takeda Pharmaceutical has freed its U.S.-based Millennium biotech unit to seek its own mergers and acquisitions among the more modest players in the drug making industry. CEO Deborah Dunshire said in an interview that Millennium is not likely to try to acquire a large company, noting Takeda's own avoidance of such deals. She said a Millennium M&A is likely to center on "smaller, single-product acquisitions." She did not, however, rule out a larger transaction as big as the $10 billion range. (Click here for more - a subscription may be required
You may also be interested in...
Scrip M&A Podcast: Which Companies Could Be Acquired Next?
The editorial team from Scrip discusses the M&A potential of various emerging biopharmas, such as Viking, Verona, Altimmune, Xenon and Crinetics.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.